vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Mega Matrix Inc (MPU). Click either name above to swap in a different company.

Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $6.1M, roughly 1.3× Mega Matrix Inc). Mega Matrix Inc runs the higher net margin — -177.4% vs -766.0%, a 588.6% gap on every dollar of revenue. On growth, Mega Matrix Inc posted the faster year-over-year revenue change (-40.9% vs -79.3%).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

ACLX vs MPU — Head-to-Head

Bigger by revenue
ACLX
ACLX
1.3× larger
ACLX
$8.1M
$6.1M
MPU
Growing faster (revenue YoY)
MPU
MPU
+38.4% gap
MPU
-40.9%
-79.3%
ACLX
Higher net margin
MPU
MPU
588.6% more per $
MPU
-177.4%
-766.0%
ACLX

Income Statement — Q1 FY2025 vs Q3 FY2025

Metric
ACLX
ACLX
MPU
MPU
Revenue
$8.1M
$6.1M
Net Profit
$-62.3M
$-10.8M
Gross Margin
47.7%
Operating Margin
-847.6%
-156.3%
Net Margin
-766.0%
-177.4%
Revenue YoY
-79.3%
-40.9%
Net Profit YoY
-765.1%
-291.1%
EPS (diluted)
$-1.13
$-0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
MPU
MPU
Q3 25
$6.1M
Q2 25
$7.1M
Q1 25
$8.1M
$7.7M
Q4 24
$15.3M
Q3 24
$26.0M
$10.3M
Q2 24
$27.4M
Q1 24
$39.3M
Q4 23
$63.1M
Net Profit
ACLX
ACLX
MPU
MPU
Q3 25
$-10.8M
Q2 25
$-1.5M
Q1 25
$-62.3M
$-2.5M
Q4 24
$-47.1M
Q3 24
$-25.9M
$-2.8M
Q2 24
$-27.2M
Q1 24
$-7.2M
Q4 23
$19.8M
Gross Margin
ACLX
ACLX
MPU
MPU
Q3 25
47.7%
Q2 25
58.5%
Q1 25
55.8%
Q4 24
Q3 24
58.5%
Q2 24
Q1 24
Q4 23
Operating Margin
ACLX
ACLX
MPU
MPU
Q3 25
-156.3%
Q2 25
-21.6%
Q1 25
-847.6%
-32.8%
Q4 24
-348.2%
Q3 24
-129.1%
-26.0%
Q2 24
-127.8%
Q1 24
-40.3%
Q4 23
23.8%
Net Margin
ACLX
ACLX
MPU
MPU
Q3 25
-177.4%
Q2 25
-20.7%
Q1 25
-766.0%
-32.0%
Q4 24
-308.4%
Q3 24
-99.4%
-26.8%
Q2 24
-99.3%
Q1 24
-18.3%
Q4 23
31.4%
EPS (diluted)
ACLX
ACLX
MPU
MPU
Q3 25
$-0.21
Q2 25
$-0.04
Q1 25
$-1.13
$-0.07
Q4 24
$-0.87
Q3 24
$-0.48
$-0.08
Q2 24
$-0.51
Q1 24
$-0.14
Q4 23
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
MPU
MPU
Cash + ST InvestmentsLiquidity on hand
$543.3M
$9.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$416.9M
$37.4M
Total Assets
$648.1M
$42.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
MPU
MPU
Q3 25
$9.8M
Q2 25
$4.0M
Q1 25
$543.3M
$6.8M
Q4 24
$587.4M
Q3 24
$574.3M
$9.9M
Q2 24
$516.7M
Q1 24
$573.9M
Q4 23
$702.0M
Stockholders' Equity
ACLX
ACLX
MPU
MPU
Q3 25
$37.4M
Q2 25
$10.9M
Q1 25
$416.9M
$11.9M
Q4 24
$454.8M
Q3 24
$483.0M
$15.8M
Q2 24
$487.2M
Q1 24
$496.6M
Q4 23
$485.4M
Total Assets
ACLX
ACLX
MPU
MPU
Q3 25
$42.7M
Q2 25
$16.6M
Q1 25
$648.1M
$17.3M
Q4 24
$711.3M
Q3 24
$764.9M
$22.4M
Q2 24
$734.3M
Q1 24
$779.7M
Q4 23
$825.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
MPU
MPU
Operating Cash FlowLast quarter
$-63.1M
$-3.5M
Free Cash FlowOCF − Capex
$-63.9M
FCF MarginFCF / Revenue
-786.4%
Capex IntensityCapex / Revenue
9.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-122.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
MPU
MPU
Q3 25
$-3.5M
Q2 25
$-1.8M
Q1 25
$-63.1M
$-2.2M
Q4 24
$-46.0M
Q3 24
$30.7M
Q2 24
$-36.2M
Q1 24
$-31.9M
Q4 23
$58.2M
Free Cash Flow
ACLX
ACLX
MPU
MPU
Q3 25
Q2 25
Q1 25
$-63.9M
Q4 24
$-47.5M
Q3 24
$28.4M
Q2 24
$-39.5M
Q1 24
$-38.3M
Q4 23
$53.0M
FCF Margin
ACLX
ACLX
MPU
MPU
Q3 25
Q2 25
Q1 25
-786.4%
Q4 24
-311.3%
Q3 24
109.2%
Q2 24
-144.1%
Q1 24
-97.7%
Q4 23
83.9%
Capex Intensity
ACLX
ACLX
MPU
MPU
Q3 25
Q2 25
Q1 25
9.6%
Q4 24
9.8%
Q3 24
8.8%
Q2 24
11.7%
Q1 24
16.4%
Q4 23
8.4%
Cash Conversion
ACLX
ACLX
MPU
MPU
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
2.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons